ICYMI, some of the content featured this week includes stories on rosacea pathogens, IL-17 and IL-23 inhibitors for psoriasis, navigating practice challenges during a pandemic, and more.
In case you missed it, some of this week’s featured content includes stories on IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis, how microbiota may impact rosacea, the future role of telehealth after the pandemic, navigating COVID-19-related practice challenges, new National Psoriasis Foundation (NPF) COVID-19 Task Force guidance statements, plus more.
This week’s edition of The Mainstream Patient features stories on the benefits of lactic acid, itchy skin during the winter, tretinoin, 2021’s biggest beauty trend, plus more.
A recent study finds that payer sway in a region hurts not only patient care, but also physician pay.
Arcutis Biotherapeutics announces the commencement of two identical phase 3 clinical trials evaluating topical PDE4 inhibitor roflumilast cream in patients with mild-to-moderate atopic dermatitis.
One expert says the action of demodex folliculorum and the composition of the symbiotic microbiota in the skin of patients with rosacea may provide valuable insights into the pathogenesis and pathophysiology of this widespread skin disease.
MJH Life Sciences COVID-19 Coalition webinar on Jan. 26 will focus on COVID-19 variants emerging around the globe.
Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.
George Martin, MD, program director of the 2021 Maui Derm Live and Maui Derm Connect annual conferences being held January 25-29 in Maui, Hawaii, shares his checklist of essential advice for optimizing practice management during the COVID-19 pandemic.
New guidance statements related to COVID-19 vaccines and psoriatic disease patients have been published by the National Psoriasis Foundation (NPF) COVID-19 Task Force.